StockData
Medtronic plc logo

Medtronic plc (MDT) operating KPIs

MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 3, 2026Score 19/303% below fair value
$96.54−0.57 (-0.59%)

Close on Oct 30, 2026Market cap $123.49BP/E 23.7Yield 2.94%

Medtronic diabetes Portfolio (Consolidated Segment) — Emerging Markets Organic Growth (Legacy through FY2024Q4, %) (%)

Medtronic Form 8-K Geographic Revenue Tables (FY2016–FY2024)

Latest, FY2024
16.6%
Period ended Apr 30, 2024
Change on a year earlier
+4.1 pts
12.5% in FY2023
History
8 years
Since FY2016
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDiabetes Portfolio (Consolidated Segment) — Emerging Markets Organic Growth (Legacy through FY2024Q4, %) (%)Year on yearSource
FY2024Apr 30, 202416.6%+4.1 ptsMedtronic SEC 8K_EARNINGS — FY2024Q4 (filed 2024-05-23) ↗
FY2023Apr 30, 202312.5%-13.2 ptsMedtronic SEC 8K_EARNINGS — FY2023Q4 (filed 2023-05-25) ↗
FY2022Apr 30, 202225.7%+21.2 ptsMedtronic SEC 8K_EARNINGS — FY2022Q4 (filed 2022-05-26) ↗
FY2021Apr 30, 20214.5%-12.0 ptsMedtronic SEC 8K_EARNINGS — FY2021Q4 (filed 2021-05-27) ↗
FY2020Apr 30, 202016.5%–Medtronic SEC 8K_EARNINGS — FY2020Q4 (filed 2020-05-21) ↗
FY2018Apr 30, 201812.0%-143.0 ptsMedtronic SEC 8K_EARNINGS — FY2018Q4 (filed 2018-05-24) ↗
FY2017Apr 30, 2017155.0%+12.0 ptsMedtronic SEC 8K_EARNINGS — FY2017Q4 (filed 2017-05-25) ↗
FY2016Apr 30, 2016143.0%–Medtronic SEC 8K_EARNINGS — FY2016Q4 (filed 2016-05-31) ↗

Cite this data

StockData. (2026). Medtronic Diabetes Portfolio (Consolidated Segment) — Emerging Markets Organic Growth (Legacy through FY2024Q4, %) (%), annual FY2016–FY2024 [Data set]. Compiled from Medtronic SEC filings and investor materials. https://stockdatahq.com/stocks/mdt/kpis/diab-seg-em-leg-org

See every metric in the Medtronic KPI table. Data updated Oct 31, 2026.